Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric L Simpson

Showing results (211-220 of 315) with videos related to

Pageof 32
Sort By:
Journal of the American Academy of Dermatology|January 12, 2020
Measuring atopic eczema symptoms in clinical practice: The first consensus statement from the Harmonising Outcome Measures for Eczema in clinical practice initiativeYael A Leshem, Joanne R Chalmers, Christian Apfelbacher, et al.
Journal of the American Academy of Dermatology|January 22, 2018
Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE)Eric L Simpson, Carsten Flohr, Lawrence F Eichenfield, et al.
American Journal of Clinical Dermatology|September 1, 2018
Major Comorbidities of Atopic Dermatitis: Beyond Allergic DisordersAmy Paller, Jennifer C Jaworski, Eric L Simpson, et al.
American Journal of Clinical Dermatology|February 8, 2026
Expert Recommendations for the Diagnosis and Management of Chronic Hand Eczema in the United StatesJonathan I Silverberg, David Cohen, Emma Guttman-Yassky, et al.
The Journal of Investigative Dermatology|April 1, 2018
Patients with Atopic Dermatitis Colonized with Staphylococcus aureus Have a Distinct Phenotype and EndotypeEric L Simpson, Miguel Villarreal, Brett Jepson, et al.
Journal of the American Academy of Dermatology|October 9, 2007
Orf-induced immunobullous disease: A distinct autoimmune blistering disorderKevin P White, Daniel C Zedek, Wain L White, et al.
American Journal of Clinical Dermatology|June 18, 2024
Integrated Safety Update of Abrocitinib in 3802 Patients with Moderate-to-Severe Atopic Dermatitis: Data from More than 5200 Patient-Years with Up to 4 Years of ExposureEric L Simpson, Jonathan I Silverberg, Audrey Nosbaum, et al.
American Journal of Clinical Dermatology|November 15, 2024
Ruxolitinib Cream Monotherapy Improved Symptoms and Quality of Life in Adults and Adolescents with Mild-to-Moderate Atopic Dermatitis: Patient-Reported Outcomes from Two Phase III StudiesEric L Simpson, Matthias Augustin, Diamant Thaçi, et al.
American Journal of Clinical Dermatology|September 8, 2023
Tralokinumab Efficacy Over 1 Year in Adults with Moderate-to-Severe Atopic Dermatitis: Pooled Data from Two Phase III TrialsEric L Simpson, Andrew E Pink, Andrew Blauvelt, et al.
American Journal of Clinical Dermatology|March 28, 2026
Safety and Efficacy of Treatment with Dupilumab for up to 2 Years in Infants and Young Children with Atopic DermatitisAmy S Paller, Eric L Simpson, Elaine C Siegfried, et al.
Pageof 32

Showing results (211-220 of 315) with videos related to

Sort By:
Pageof 32
Journal of the American Academy of Dermatology|January 12, 2020
Measuring atopic eczema symptoms in clinical practice: The first consensus statement from the Harmonising Outcome Measures for Eczema in clinical practice initiativeYael A Leshem, Joanne R Chalmers, Christian Apfelbacher, et al.
Journal of the American Academy of Dermatology|January 22, 2018
Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE)Eric L Simpson, Carsten Flohr, Lawrence F Eichenfield, et al.
American Journal of Clinical Dermatology|September 1, 2018
Major Comorbidities of Atopic Dermatitis: Beyond Allergic DisordersAmy Paller, Jennifer C Jaworski, Eric L Simpson, et al.
American Journal of Clinical Dermatology|February 8, 2026
Expert Recommendations for the Diagnosis and Management of Chronic Hand Eczema in the United StatesJonathan I Silverberg, David Cohen, Emma Guttman-Yassky, et al.
The Journal of Investigative Dermatology|April 1, 2018
Patients with Atopic Dermatitis Colonized with Staphylococcus aureus Have a Distinct Phenotype and EndotypeEric L Simpson, Miguel Villarreal, Brett Jepson, et al.
Journal of the American Academy of Dermatology|October 9, 2007
Orf-induced immunobullous disease: A distinct autoimmune blistering disorderKevin P White, Daniel C Zedek, Wain L White, et al.
American Journal of Clinical Dermatology|June 18, 2024
Integrated Safety Update of Abrocitinib in 3802 Patients with Moderate-to-Severe Atopic Dermatitis: Data from More than 5200 Patient-Years with Up to 4 Years of ExposureEric L Simpson, Jonathan I Silverberg, Audrey Nosbaum, et al.
American Journal of Clinical Dermatology|November 15, 2024
Ruxolitinib Cream Monotherapy Improved Symptoms and Quality of Life in Adults and Adolescents with Mild-to-Moderate Atopic Dermatitis: Patient-Reported Outcomes from Two Phase III StudiesEric L Simpson, Matthias Augustin, Diamant Thaçi, et al.
American Journal of Clinical Dermatology|September 8, 2023
Tralokinumab Efficacy Over 1 Year in Adults with Moderate-to-Severe Atopic Dermatitis: Pooled Data from Two Phase III TrialsEric L Simpson, Andrew E Pink, Andrew Blauvelt, et al.
American Journal of Clinical Dermatology|March 28, 2026
Safety and Efficacy of Treatment with Dupilumab for up to 2 Years in Infants and Young Children with Atopic DermatitisAmy S Paller, Eric L Simpson, Elaine C Siegfried, et al.
Pageof 32